Vaccines, HIV, respiratory and emerging infectious disease: procurement, approvals and public health response.
Vaccines, HIV, respiratory and emerging infectious disease: procurement, approvals and public health response.
Measles infections in the United States and Mexico have already exceeded all of 2025, with Pennsylvania recording five deaths and more than 1,000 infections as vaccine exemptions reach an all-time …
With 55,792 confirmed measles cases and 77 deaths across the Americas in 2026, PAHO warns that upcoming religious mass gatherings in South America could accelerate transmission in a region where …
Moderna and Laboratorios Liomont signed a license, distribution and supply agreement for Mexico’s COVID-19 vaccines, with phased messenger RNA (mRNA) technology transfer, as Mexico’s state-owned BIRMEX awarded Liomont an open …
Ministerial Resolution 929-2026/MINSA updates Peru’s national essential medicines formulary with eight HIV and hepatitis products, including a once-daily pediatric HIV tablet for about 500 children and options for more than …
The FDA approved GSK and Ionis’s bepirovirsen for a narrow group of adults with chronic hepatitis B; 19% of treated trial patients still had the virus controlled, with hepatitis B …
A committee of Conitec, Brazil’s health technology assessment body, provisionally recommended ViiV’s HIV-prevention injection at its proposed price of about R$6,660 a year, while Brazil offered Gilead roughly a third …
Biolab, a Brazilian pharmaceutical company, has been selected by the UN-backed Medicines Patent Pool to manufacture and sell baloxavir marboxil (Xofluza), Roche’s single-dose oral influenza treatment, in Brazil under a …
Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
Colombia’s Ministry of Health declared public interest grounds to pursue mandatory licensing of Gilead’s sofosbuvir-based hepatitis C patents, transferring the process to the competition authority for a final determination.
WHO declared a Public Health Emergency of International Concern on May 16 after 246 suspected cases and 80 deaths in DRC’s Ituri province. Bundibugyo species has no approved countermeasures.
You must be logged in to post a comment.